Here, we describe methods for evaluating systemic delivery of miR-7 using a lipidnanoparticle formulation in an animal model.
2
The '069 patent relates to lipidnanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
3
Low drug encapsulation efficiency and burst release are the main drawbacks of lipidnanoparticles.
4
The results after tail iv administration of oridonin and oridonin solid lipidnanoparticles were compared.
5
To solve these problems, lipidnanoparticles containing a cross-linked lipid network were prepared in this study.
6
The concentration-time curves of oridonin and oridonin solid lipidnanoparticles were both fitted to the three-compartment model.
7
Solid lipidnanoparticles were helpful for oridonin to reach a long circulation time and were hopeful to be its novel drug carrier.
8
The physicochemical properties of these lipidnanoparticles such as average diameter, drug loading, drug encapsulation efficiency and in vitro drug release were investigated.